...
机译:一流的ERK1 / 2抑制剂Ulixertinib(BVD-523)在MAPK突变体高级实体瘤患者中:I相剂量 - 升级和扩展研究的结果
Harvard Med Sch Massachusetts Gen Hosp Canc Ctr Boston MA USA;
Tennessee Oncol Sarah Cannon Res Inst Nashville TN USA;
Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;
Univ Calif Los Angeles David Geffen Sch Med Los Angeles CA 90095 USA;
Vanderbilt Univ Med Ctr Nashville TN USA;
Vanderbilt Univ Med Ctr Nashville TN USA;
Florida Canc Specialists Sarah Cannon Res Inst Sarasota FL USA;
Harvard Med Sch Dana Farber Canc Inst Boston MA USA;
Beth Israel Deaconess Med Ctr Boston MA 02215 USA;
South Texas Accelerated Res Therapeut San Antonio TX USA;
Washington Univ St Louis MO USA;
Yale Univ New Haven CT USA;
Harvard Med Sch Massachusetts Gen Hosp Canc Ctr Boston MA USA;
Harvard Med Sch Dana Farber Canc Inst Boston MA USA;
Mem Sloan Kettering Canc Ctr 1275 York Ave New York NY 10021 USA;
Mem Sloan Kettering Canc Ctr 1275 York Ave New York NY 10021 USA;
Mem Sloan Kettering Canc Ctr 1275 York Ave New York NY 10021 USA;
Univ Calif Los Angeles David Geffen Sch Med Los Angeles CA 90095 USA;
Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;
BioMed Valley Discover Inc Kansas City MO USA;
BioMed Valley Discover Inc Kansas City MO USA;
BioMed Valley Discover Inc Kansas City MO USA;
BioMed Valley Discover Inc Kansas City MO USA;
BioMed Valley Discover Inc Kansas City MO USA;
BioMed Valley Discover Inc Kansas City MO USA;
Mem Sloan Kettering Canc Ctr 1275 York Ave New York NY 10021 USA;
Mem Sloan Kettering Canc Ctr 1275 York Ave New York NY 10021 USA;
机译:一流的ERK1 / 2抑制剂Ulixertinib(BVD-523)在MAPK突变体高级实体瘤患者中:I相剂量 - 升级和扩展研究的结果
机译:评价BGJ398,一种成纤维细胞生长因子受体1-3激酶抑制剂,患有成纤维细胞生长因子受体的遗传改变的患者:全球阶段I,剂量升级和剂量扩展研究的结果(Vol 35,PG 157,2017)
机译:口服泛I类PI3K抑制剂buparlisib(BKM120)在晚期实体瘤患者中的I期剂量递增和扩展研究
机译:患者临床试验与患有转移和/或复发性固体瘤的患者的HER-2 B细胞嵌合和多型肽疫苗
机译:长春新碱,伊非替康,替莫唑胺和贝伐单抗(VIT-B)逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
机译:晚期实体瘤患者中PARP抑制剂氟唑帕布(SHR3162)的I期剂量递增和扩增研究
机译:PARP抑制剂,Fluzoparib(SHR3162)的I相剂量升级和扩展研究,高级实体瘤患者